Your browser doesn't support javascript.
loading
FBXO5 acts as a novel prognostic biomarker for patients with cervical cancer.
Jiang, Shan; Zheng, Jianfeng; Cui, Zhaolei; Li, Yanhong; Wu, Qiaoling; Cai, Xintong; Zheng, Chaoqiang; Sun, Yang.
Affiliation
  • Jiang S; Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Zheng J; College of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China.
  • Cui Z; Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Li Y; Laboratory of Biochemistry and Molecular Biology Research, Department of Clinical Laboratory, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Wu Q; Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Cai X; College of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China.
  • Zheng C; Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Sun Y; Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Front Cell Dev Biol ; 11: 1200197, 2023.
Article in En | MEDLINE | ID: mdl-37457292
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Front Cell Dev Biol Year: 2023 Document type: Article Affiliation country: China Country of publication: Suiza
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Front Cell Dev Biol Year: 2023 Document type: Article Affiliation country: China Country of publication: Suiza